Shots:
- Alvotech has entered a strategic licensing & commercialization agreement with Lotus Pharmaceutical for AVT34, a proposed Imfinzi (durvalumab) biosimilar, & AVT87, a proposed Hemlibra (emicizumab) biosimilar, in the US & selected Asian markets
- Under the US semi-exclusive deal, Alvotech & Lotus will jointly commercialize AVT34 and AVT87, with Lotus commercializing the products through Alvogen; Alvotech will lead development, US marketing authorizations & serve as the exclusive supplier across all markets
- Lotus will hold exclusive commercialization rights for AVT34 & AVT87 in eight Asian markets, handling local regulatory submissions & commercialization, while Alvotech could receive ~$150M in upfront & milestone payments plus ongoing commercial product supply revenues
Ref: Globenewswire | Image: Alvotech & Lotus | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
